Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 convention...

Cijeli opis

Bibliografski detalji

Glavni autori:	Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2024-03-01
Serija:	Rheumatology and Therapy
Teme:	bDMARD-IR csDMARD-IR IL-23 KEEPsAKE 2 Long-term treatment Psoriatic arthritis
Online pristup:	https://doi.org/10.1007/s40744-024-00657-2
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!